Island Pharmaceuticals is an Australian pharmaceutical company developing a pipeline of small molecule anti-virals. Focused of viruses with significant unmet medical need, we have two clinical stage programs. Both programs are currently eligible for priority review vouchers. A recently acquired program, Galidesivir, is being advanced for Marburg virus infections while a second program (ISLA-101) is being advanced for dengue and other mosquito borne viruses. Galidesivir is being advanced via the Animal Rule with confirmatory NHP studies expected to commence shortly. ISLA-101 has recently announced successful results in a Phase 2a study in dengue infected subjects. We are now making plans for its further clinical development.